Investors

Media Coverage

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Media Coverage

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush? [Microdose]

August 28, 2025

Reimagining Psychedelics: Mental Wellness Without the Roadblocks [Pharmaceutical Online]

August 19, 2025

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets [Microdose]

August 18, 2025

The Future Of Psychedelic-Inspired Therapeutics: No-Trip Neuroplastogens [Life Science Leader]

August 14, 2025

Six psychedelic drug companies aiming to revolutionize mental health treatment [Labiotech]

August 12, 2025

Stimulating Neuroplasticity for Therapeutic Benefits Inspired by Psychedelic Research [High on Healthy]

July 20, 2025

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment [Microdose]

July 15, 2025

EB-003 Targets 5‑HT1B: Expanding Mental Health Promise [Meditech Today]

July 2, 2025

Enveric’s EB-003 Shows Dual Mechanism Promise, Paving a New Path in Neuropsychiatric Drug Innovation [Microdose]

July 1, 2025

Enveric’s Patent Win Targets New Frontiers in Sleep Medicine [Microdose]

June 3, 2025

1
2
3
…
14
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2025 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.